Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Multiple Myeloma (MM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Early research (Phase 1)UnknownNCT05052970
What this trial is testing

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 60
Early research (Phase 1)Study completedNCT02955550
What this trial is testing

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Celularity Incorporated 15
Early research (Phase 1)Not Yet RecruitingNCT07735546
What this trial is testing

UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma (MM)
Umoja Biopharma 100
Not applicableUnknownNCT04447573
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT01946477
What this trial is testing

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Who this might be right for
Multiple Myeloma
Celgene 186
Early research (Phase 1)Looking for participantsNCT07409246
What this trial is testing

Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
AbbVie 127
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997
What this trial is testing

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 939
Early research (Phase 1)Study completedNCT02992483
What this trial is testing

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)Study completedNCT02185820
What this trial is testing

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 57
Early research (Phase 1)Study completedNCT02497378
What this trial is testing

JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 8
Testing effectiveness (Phase 2)Study completedNCT01394354
What this trial is testing

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma in Relapse
University Hospital Freiburg 34
Early research (Phase 1)Study completedNCT00642954
What this trial is testing

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC 31
Large-scale testing (Phase 3)Study completedNCT00179647
What this trial is testing

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene Corporation 1,913
Early research (Phase 1)Study completedNCT01582295
What this trial is testing

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 4
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)WithdrawnNCT02658396
What this trial is testing

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07771361
What this trial is testing

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ RelapsedMultiple Myeloma RefractoryMultiple Myeloma in Relapse+5 more
Luminary Therapeutics 90
Testing effectiveness (Phase 2)Study completedNCT03242460
What this trial is testing

The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

Who this might be right for
Relapsed and/or refractorY Multiple Myeloma
Kosin University Gospel Hospital 55
Very early researchUnknownNCT04412889
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Who this might be right for
Multiple Myeloma
Hebei Yanda Ludaopei Hospital 18
Next Page